Skip to main content
OpenTrials
Completed

NCT Number: NCT06577064

Sacral Erector Spinae Block for Pilonidal Sinus Surgery

The incidence of pilonidal sinus disease (PD) is estimated to be around 26/100,000 individuals mostly men.PD can cause the development of abscess or a draining sinus tract and that may lead to a loss of productive power and long-term morbidity.Different surgical technique approaches were proposed for treatment with different rates of success.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Medicine Menoufia University

Cairo, Governorate, 32511, Egypt

About this study

Sacral erector spinae plane block was first described by Tulgar et al. To provide sensory blockade in the parasacral region in two cases who had pilonidal sinus surgeries. Since then, the block was used for multiple surgeries like anorecatal, hip surgery and parasacral reconstructive surgeries.After obtaining the ethical committee approval from Menoufia University. patients scheduled for pilonidal sinus surgery will be randomly allocated into one of two groups Patients will be randomized to a study group using a computer-generated random number table, and the allocation concealment will be performed using a sealed envelope technique.The sealed opaque envelopes will be kept locked in dedicated research safe and will be accessed by a research coordinator only when a patient consented for the study. The anesthetist will perform the intervention with the doses and concentration of drugs as per the protocol.

The patients and the follow up researcher will be blinded to the type of intervention used. The patient follow-up time will be scheduled intraoperatively PACU, 1 hour and 24hours postoperatively. The anesthetist who did the intervention will have no access to the reported documents or contact with the patient postoperatively.

For induction of anesthesia all patients will receive medication as per the facility protocol where propofol 1-2mg/Kg, fentanyl 2μg/Kg (actual BW), rocuronium 0.5 mg/kg will be used for induction and an endotracheal tube intubation will be inserted to secure the airway. After intubation and confirmation of endotracheal tube placement by auscultation and capnography, the patient will be turned into prone position.

Maintenance of anesthesia will be maintained by sevoflurane 1-1.2 MAC and rocuronium 0.1mg/kg guided by the TOF. All patients will receive multimodal analgesia in the form of paracetamol 1gm and parecoxib 40 mg (Pizer manufacturing Belgium). After exclusion of other causes of tachycardia and hypertension Morphine 2mg increments will be administrated to keep the heart rate or blood pressure within 20 percent of the patient's baseline parameters.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years old
  • ASA physical status 1-3

Exclusion criteria

  • ASA >3
  • Opioid use within the previous 3 months
  • Deranged coagulation parameters
  • Patient refusal
  • Allergy to local anesthetic medication.
  • Preoperative neurological deficits

Treatment and study plan

Sacral Erector Spinae Plane Block

Procedure

30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side

Primary outcomes

  1. Pain score

    Time frame: 24 hours

    NRS scor for post operative pain scale from 0 to 100

Secondary outcomes

  1. Opioid consumption.

    Time frame: 24 hours

    Total opioid consumbtion in mg

  2. Lower limb motor affection

    Time frame: 24 hours

    Modified Bromage scale for motor affection from 1 to 6

  3. Adverse effects

    Time frame: 24 hours

    Side effect as nausea, vomiting, itching will be recorded

Sponsors and collaborators

Lead sponsor

Menoufia University

Other

Registry information

Official study title

Sacral Erector Spinae Block for Pilonidal Sinus Surgery: A Randomized Controlled Trial

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Aug 29, 2024
Registry last updated
Aug 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.